Objective Our objective was to assess the pharmacokinetics of erlotinib in a large patient
population with solid tumors, identify covariates, and explore relationships between …

Purpose: To compare the pharmacokinetic variables of erlotinib in current smokers with
nonsmokers after receiving a single oral 150 or 300 mg dose of erlotinib. Experimental …

Introduction BR. 21 demonstrated significant survival benefit for non-small cell lung cancer
patients receiving erlotinib compared with placebo. We undertook to characterize, by …

Background Erlotinib shows large inter-patient pharmacokinetic variability, but the impact of
early drug exposure and genetic variations on the clinical outcomes of erlotinib remains fully …

Purpose Cigarette smoking induces CYP1A1/1A2 and is hypothesized to alter erlotinib
pharmacokinetics. This study aimed to determine the maximum tolerated dose (MTD) of …

BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …

Purpose The objectives of this phase I dose-finding study of erlotinib were to investigate the
toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess …

Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …

Purpose: To examine potential markers of clinical benefit and the effects of erlotinib on the
epidermal growth factor receptor (EGFR) signaling pathway in advanced non–small cell …

Purpose Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR)
tyrosine kinase inhibitor. This phase II study of erlotinib in patients with HER1/EGFR …